Drugmaker Amgen Invests $200 mn to Establish AI-Driven Biotechnology Innovation Centre in Hyderabad
This state-of-the-art facility will focus on enhancing the discovery and development of next-generation medicines.
U.S.-based biopharmaceutical leader Amgen has announced an initial $200 million investment to establish a cutting-edge Biotechnology Innovation Center in Hyderabad, India.
Unveiled by Amgen CEO Robert Bradway during the inauguration ceremony, this investment signals the company's commitment to leveraging artificial intelligence (AI) and data science in the accelerated development of innovative drugs.
This state-of-the-art facility will focus on advancing healthcare solutions by utilizing AI-driven technologies to enhance the discovery and development of next-generation medicines.
The centre is part of Amgen's global strategy to improve operational efficiency and bring innovative therapies to patients worldwide faster.
“We have long envisioned expanding Amgen’s presence in India, and the time has finally come. This $200 million investment is just the beginning, with additional investments planned in the coming years,” said Bradway. The new centre is expected to employ approximately 2,000 professionals by 2025, with 300 employees already on board.
This expansion underscores India’s growing prominence as a hub for healthcare innovation and will play a crucial role in advancing the Indian healthcare sector. It will foster collaborations with academic institutions, provide skill development programs, and create research partnerships aligned with Telangana’s vision of becoming a global biotechnology hub.
Telangana Chief Minister A. Revanth Reddy, who inaugurated the centre, expressed the state’s dedication to establishing Hyderabad as a world-class biotech destination. “Hyderabad is rapidly transforming into a world-class biotech hub. We welcome Amgen’s expansion, which will not only drive innovation but also create high-value jobs and promote collaborative research,” said Reddy.
Amgen’s Investment Impact on India’s Life Sciences Ecosystem
Amgen’s investment in India is a pivotal step in strengthening India’s life sciences ecosystem. The new Biotechnology Innovation Center will boost India’s capabilities in precision medicine, clinical research, and biotechnology, further solidifying the country’s position as the “pharmacy of the world.”
The initiative also aligns with the U.S.-India Trust Initiative, which aims to promote collaboration in emerging technologies. Jennifer Larson, U.S. Consul General in Hyderabad, emphasized the significance of the partnership: “Amgen’s investment exemplifies how our nations can work together to harness innovation, talent, and technology.”
Last year, Amgen appointed Naveen Gullapalli as its Managing Director, to oversee the company’s India Technology and Innovation site in Hyderabad.
Gullapalli brings a wealth of experience in leading global operations and managing critical functions across the pharmaceutical, finance, and technology industries.
Before joining Amgen, Gullapalli held a prominent role at Novartis, where he spearheaded the development of their global center in Hyderabad and managed a network of six centers worldwide.
